Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Church who wrote (2985)	11/25/1997 9:30:00 PM
From: Oliver & Co	Respond to of 6136

For the HIV/AIDS Update Conference that I gave last week at Cedars Med Ctr, Miami. Agouron sent me a slide with their treatment data. 900,000 HIV + Pts US Undiagnosed-------------------32%------289K Diagnosed/Not under Care------33%------297K Diagnosed/Under Care----------35%------314k of these: PI+ 22%-----Crix--79K (40% of PI scripts) Virac-56K (29%) Inv---38K (19%) Norv--24K (12%) PI-(without PI) 6%-54K No Therapy -----7%-63K If you remember my post of Nov 16, with the Sept numbers, they had Cryx-78K Vir--47K Inv--37K Nor--21K And the # of Dxd/under care up by 20K. Which leads me to believe that most new patients are being started on Viracept.